Alterations and Mechanism of Gut Microbiota in Graves' Disease and Hashimoto's Thyroiditis

From BugSigDB
Needs review
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI Uniform resource identifier for web resources.
Authors
Zhao H, Yuan L, Zhu D, Sun B, Du J, Wang J
Journal
Polish journal of microbiology
Year
2022
Keywords:
Graves’ disease, Hashimoto’s thyroiditis, autoimmune thyroid disease, gut microbiota
To explore the role of gut microbiota in Graves' disease (GD) and Hashimoto's thyroiditis (HT). Seventy fecal samples were collected, including 27 patients with GD, 27 with HT, and 16 samples from healthy volunteers. Chemiluminescence was used to detect thyroid function and autoantibodies (FT3, FT4, TSH, TRAb, TGAb, and TPOAb); thyroid ultrasound and 16S sequencing were used to analyze the bacteria in fecal samples; KEGG (Kyoto Encyclopedia of Genes and Genomes) and COG (Clusters of Orthologous Groups) were used to analyze the functional prediction and pathogenesis. The overall structure of gut microbiota in the GD and HT groups was significantly different from the healthy control group. Proteobacteria and Actinobacteria contents were the highest in the HT group. Compared to the control group, the GD and HT groups had a higher abundance of Erysipelotrichia, Cyanobacteria, and Ruminococcus_2 and lower levels of Bacillaceae and Megamonas. Further analysis of KEGG found that the "ABC transporter" metabolic pathway was highly correlated with the occurrence of GD and HT. COG analysis showed that the GD and HT groups were enriched in carbohydrate transport and metabolism compared to the healthy control group but not in amino acid transport and metabolism. Our data suggested that Bacillus, Blautia, and Ornithinimicrobium could be used as potential markers to distinguish GD and HT from the healthy population and that "ABC transporter" metabolic pathway may be involved in the pathogenesis of GD and HT.

Experiment 1


Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Graves disease Basedow disease,Basedow's disease,exophthalmic goiter,Flajani-Basedow-Graves disease,grave's disease,Graves disease,Graves' disease,Graves' hyperthyroidism,parry disease,toxic diffuse goiter,graves disease
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Hypothyroidism group (HT) + Normal
Group 1 name Corresponds to the case (exposed) group for case-control studies
Graves’ disease/Hyperthyroidism (GD)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients diagnosed with Graves’ disease(GD) also known as the Hyperthyroidism group
Group 0 sample size Number of subjects in the control (unexposed) group
43
Group 1 sample size Number of subjects in the case (exposed) group
27
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
Three months

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
LEfSe
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
3


Signature 1

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 2A

Description: LEfSe shows the greatest difference in abundance (taxa) between the three groups (LDA threshold > 3).

Abundance in Group 1: increased abundance in Graves’ disease/Hyperthyroidism (GD)

NCBI Quality ControlLinks
Blautia
Eubacterium ventriosum
Dorea
Lachnospiraceae bacterium NK4A136
Lachnospira
Coprococcus
Ruminococcus
Erysipelotrichaceae
Erysipelotrichales
Erysipelotrichia
Prevotella
Parasutterella

Revision editor(s): Aleru Divine

Experiment 2


Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Differences from previous experiment shown

Subjects

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Hashimoto's thyroiditis autoimmune thyroiditis,chronic lymphocytic thyroiditides,chronic lymphocytic thyroiditis,disease, Hashimoto,disease, Hashimoto's,Hashimoto disease,Hashimoto struma,Hashimoto syndrome,Hashimoto thyroiditides,Hashimoto Thyroiditis,Hashimoto thyroiditis,Hashimoto's disease,Hashimoto's struma,Hashimoto's syndrome,Hashimoto's syndromes,Hashimoto's thyroiditis,Hashimotos disease,Hashimotos syndrome,HT,Ht,hypothyroidism, autoimmune,hypothyroidism, autoimmune thyroid autoantibodies, included,Lymphocytic Thyroiditides,lymphocytic thyroiditides, chronic,Lymphocytic Thyroiditis,lymphocytic thyroiditis,lymphocytic thyroiditis, chronic,Lymphomatous Thyroiditides,syndrome, Hashimoto's,syndromes, Hashimoto's,thyroid autoantibodies,thyroiditides, chronic lymphocytic,thyroiditides, Hashimoto,Thyroiditides, Lymphocytic,Thyroiditides, Lymphomatous,thyroiditis, chronic lymphocytic,thyroiditis, Hashimoto,Thyroiditis, Lymphocytic,Thyroiditis, Lymphomatous,hashimoto's thyroiditis
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Graves’ disease/Hyperthyroidism (GD)+ Normal
Group 1 name Corresponds to the case (exposed) group for case-control studies
Hypothyroidism group (HT)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients diagnosed with Hashimoto’s Thyroiditis, also known as the Hypothyroidism group (HT).

Lab analysis

Statistical Analysis

Signature 1

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 2A

Description: LEfSe shows the greatest difference in abundance (taxa) between the three groups (LDA threshold > 3).

Abundance in Group 1: increased abundance in Hypothyroidism group (HT)

NCBI Quality ControlLinks
Mediterraneibacter gnavus
Ruminiclostridium
Acetanaerobacterium
Lactobacillales

Revision editor(s): Aleru Divine

Experiment 3


Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Differences from previous experiment shown

Subjects

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Graves disease , Hashimoto's thyroiditis Basedow disease,Basedow's disease,exophthalmic goiter,Flajani-Basedow-Graves disease,grave's disease,Graves disease,Graves' disease,Graves' hyperthyroidism,parry disease,toxic diffuse goiter,graves disease,autoimmune thyroiditis,chronic lymphocytic thyroiditides,chronic lymphocytic thyroiditis,disease, Hashimoto,disease, Hashimoto's,Hashimoto disease,Hashimoto struma,Hashimoto syndrome,Hashimoto thyroiditides,Hashimoto Thyroiditis,Hashimoto thyroiditis,Hashimoto's disease,Hashimoto's struma,Hashimoto's syndrome,Hashimoto's syndromes,Hashimoto's thyroiditis,Hashimotos disease,Hashimotos syndrome,HT,Ht,hypothyroidism, autoimmune,hypothyroidism, autoimmune thyroid autoantibodies, included,Lymphocytic Thyroiditides,lymphocytic thyroiditides, chronic,Lymphocytic Thyroiditis,lymphocytic thyroiditis,lymphocytic thyroiditis, chronic,Lymphomatous Thyroiditides,syndrome, Hashimoto's,syndromes, Hashimoto's,thyroid autoantibodies,thyroiditides, chronic lymphocytic,thyroiditides, Hashimoto,Thyroiditides, Lymphocytic,Thyroiditides, Lymphomatous,thyroiditis, chronic lymphocytic,thyroiditis, Hashimoto,Thyroiditis, Lymphocytic,Thyroiditis, Lymphomatous,hashimoto's thyroiditis
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Normal
Group 1 name Corresponds to the case (exposed) group for case-control studies
Graves’ disease/Hyperthyroidism (GD) + Hypothyroidism group (HT)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients diagnosed with Graves’ disease(GD), also known as the Hyperthyroidism group and patients with Hashimoto’s Thyroiditis, also known as the Hypothyroidism group (HT).
Group 0 sample size Number of subjects in the control (unexposed) group
16
Group 1 sample size Number of subjects in the case (exposed) group
54

Lab analysis

Statistical Analysis

Signature 1

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 2A

Description: LEfSe shows the greatest difference in abundance (taxa) between the three groups (LDA threshold > 3).

Abundance in Group 1: decreased abundance in Graves’ disease/Hyperthyroidism (GD) + Hypothyroidism group (HT)

NCBI Quality ControlLinks
Negativicutes
Selenomonadales
Megamonas

Revision editor(s): Aleru Divine

Experiment 4


Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Differences from previous experiment shown

Subjects

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Graves disease Basedow disease,Basedow's disease,exophthalmic goiter,Flajani-Basedow-Graves disease,grave's disease,Graves disease,Graves' disease,Graves' hyperthyroidism,parry disease,toxic diffuse goiter,graves disease
Group 1 name Corresponds to the case (exposed) group for case-control studies
Graves’ disease/Hyperthyroidism (GD)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients diagnosed with Graves’ disease(GD) also known as the Hyperthyroidism group
Group 1 sample size Number of subjects in the case (exposed) group
27

Lab analysis

Statistical Analysis

Statistical test
Mann-Whitney (Wilcoxon)
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
Not specified


Signature 1

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 2B, 2D, and 2F

Description: The difference in microbiota between the GD group or HT groups and the healthy control group at the phylum level (B, C), at the family level (D, E), and at the genus level (F, G). *p < 0.05; ** p < 0.01; ***p < 0.001.

Abundance in Group 1: decreased abundance in Graves’ disease/Hyperthyroidism (GD)

NCBI Quality ControlLinks
Deinococcota
Bacillaceae
Nocardioidaceae
Flavobacteriaceae
Dermabacteraceae
Corynebacteriaceae
Intrasporangiaceae
unclassified Selenomonadaceae
Megamonas
unclassified Peptostreptococcaceae

Revision editor(s): Aleru Divine

Signature 2

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 2B, 2D, and 2F

Description: The difference in microbiota between the GD group or HT groups and the healthy control group at the phylum level (B, C), at the family level (D, E), and at the genus level (F, G). *p < 0.05; ** p < 0.01; ***p < 0.001.

Abundance in Group 1: increased abundance in Graves’ disease/Hyperthyroidism (GD)

NCBI Quality ControlLinks
Alcaligenaceae
Blautia
Butyricicoccus
Chloroflexota
Christensenellaceae
Cyanobacteriota
Erysipelotrichaceae
Eubacteriales Family XIII. Incertae Sedis bacterium
Eubacterium ventriosum
Lachnospiraceae
Lachnospiraceae bacterium NK4A136
Mediterraneibacter gnavus
Nocardiaceae
Parasutterella
Peptococcaceae
Prevotella
Ruminiclostridium
Ruminococcus
unclassified Lachnospiraceae
Ruminococcaceae bacterium UCG-013Ruminococcaceae bacterium UCG-013
Ruminococcaceae bacterium UCG-014Ruminococcaceae bacterium UCG-014
Christensenellaceae R-7 groupChristensenellaceae R-7 group
unclassified Cyanophyceae

Revision editor(s): Aleru Divine

Experiment 5


Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Differences from previous experiment shown

Subjects

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Hashimoto's thyroiditis autoimmune thyroiditis,chronic lymphocytic thyroiditides,chronic lymphocytic thyroiditis,disease, Hashimoto,disease, Hashimoto's,Hashimoto disease,Hashimoto struma,Hashimoto syndrome,Hashimoto thyroiditides,Hashimoto Thyroiditis,Hashimoto thyroiditis,Hashimoto's disease,Hashimoto's struma,Hashimoto's syndrome,Hashimoto's syndromes,Hashimoto's thyroiditis,Hashimotos disease,Hashimotos syndrome,HT,Ht,hypothyroidism, autoimmune,hypothyroidism, autoimmune thyroid autoantibodies, included,Lymphocytic Thyroiditides,lymphocytic thyroiditides, chronic,Lymphocytic Thyroiditis,lymphocytic thyroiditis,lymphocytic thyroiditis, chronic,Lymphomatous Thyroiditides,syndrome, Hashimoto's,syndromes, Hashimoto's,thyroid autoantibodies,thyroiditides, chronic lymphocytic,thyroiditides, Hashimoto,Thyroiditides, Lymphocytic,Thyroiditides, Lymphomatous,thyroiditis, chronic lymphocytic,thyroiditis, Hashimoto,Thyroiditis, Lymphocytic,Thyroiditis, Lymphomatous,hashimoto's thyroiditis
Group 1 name Corresponds to the case (exposed) group for case-control studies
Hashimoto's thyroiditis/Hypothyroidism (GD)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients diagnosed with Hashimoto's thyroiditis also known as the Hypothyroidism group (HT).

Lab analysis

Statistical Analysis

Signature 1

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 2C, 2E, and 2G

Description: The difference in microbiota between the GD group or HT groups and the healthy control group at the phylum level (B, C), at the family level (D, E), and at the genus level (F, G). *p < 0.05; ** p < 0.01; ***p < 0.001.

Abundance in Group 1: increased abundance in Hashimoto's thyroiditis/Hypothyroidism (GD)

NCBI Quality ControlLinks
Cyanobacteriota
Enterococcaceae
Erysipelotrichaceae
Coriobacteriaceae
Eubacteriales Family XIII. Incertae Sedis bacterium
Actinomycetaceae
Micrococcaceae
unclassified Cyanophyceae
Defluviitaleaceae
Ruminococcus
Enterococcus
Mediterraneibacter gnavus
Ruminiclostridium
Actinomyces
Thomasclavelia
Rothia

Revision editor(s): Aleru Divine

Signature 2

Needs review

Curated date: 2025/07/24

Curator: Aleru Divine

Revision editor(s): Aleru Divine

Source: Figure 2C, 2E, and 2G

Description: The difference in microbiota between the GD group or HT groups and the healthy control group at the phylum level (B, C), at the family level (D, E), and at the genus level (F, G). *p < 0.05; ** p < 0.01; ***p < 0.001.

Abundance in Group 1: decreased abundance in Hashimoto's thyroiditis/Hypothyroidism (GD)

NCBI Quality ControlLinks
Chloroflexota
Deinococcota
Peptostreptococcaceae
Bacillaceae
unclassified Eubacteriales
unclassified Selenomonadales
Intrasporangiaceae
Corynebacteriaceae
Dermabacteraceae
Megamonas
Lachnospiraceae UCG 004Lachnospiraceae UCG 004
Lachnospiraceae bacterium NC2004
unclassified Peptostreptococcaceae
Bacillus
Coprobacter

Revision editor(s): Aleru Divine